$42.50
-0.14-0.33%
Pre-Market: 4:20 AM EDT
15 minutes delayed
Comments
Loading...
Bristol-Myers Squibb
BMYNYSE
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Bristol-Myers Squibb (NYSE:BMY) Stock, Analyst Ratings, Price Targets, Forecasts
Bristol-Myers Squibb Co has a consensus price target of $64.5 based on the ratings of 28 analysts. The high is $90 issued by Citigroup on May 26, 2022. The low is $41 issued by Barclays on July 10, 2024. The 3 most-recent analyst ratings were released by Barclays, BMO Capital, and Barclays on July 10, 2024, April 26, 2024, and April 26, 2024, respectively. With an average price target of $44 between Barclays, BMO Capital, and Barclays, there's an implied 3.53% upside for Bristol-Myers Squibb Co from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Barclays
BMO Capital
Wells Fargo
Redburn Atlantic
B of A Securities
1calculated from analyst ratings
Analyst Ratings for Bristol-Myers Squibb
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/10/2024 | Buy Now | -3.53% | Barclays | Carter Gould | $43 → $41 | Maintains | Equal-Weight | Get Alert |
| 04/26/2024 | Buy Now | 12.94% | BMO Capital | Evan Seigerman | $55 → $48 | Maintains | Market Perform | Get Alert |
| 04/26/2024 | Buy Now | 1.18% | Barclays | Carter Gould | $51 → $43 | Maintains | Equal-Weight | Get Alert |
| 04/18/2024 | Buy Now | 22.35% | Wells Fargo | Mohit Bansal | $51 → $52 | Maintains | Equal-Weight | Get Alert |
| 02/06/2024 | Buy Now | 20% | Wells Fargo | Mohit Bansal | $58 → $51 | Maintains | Equal-Weight | Get Alert |
| 02/06/2024 | Buy Now | 27.06% | Redburn Atlantic | Steve Chesney | $77 → $54 | Downgrade | Buy → Neutral | Get Alert |
| 01/03/2024 | Buy Now | 41.18% | B of A Securities | Geoff Meacham | $68 → $60 | Downgrade | Buy → Neutral | Get Alert |
| 12/27/2023 | Buy Now | 60% | B of A Securities | Geoff Meacham | $72 → $68 | Maintains | Buy | Get Alert |
| 11/15/2023 | Buy Now | 29.41% | Cantor Fitzgerald | Olivia Brayer | $68 → $55 | Downgrade | Overweight → Neutral | Get Alert |
| 11/09/2023 | Buy Now | 29.41% | Deutsche Bank | James Shin | → $55 | Initiates | → Hold | Get Alert |
| 11/02/2023 | Buy Now | 27.06% | Daiwa Capital | Narumi Nakagiri | $68 → $54 | Downgrade | Outperform → Neutral | Get Alert |
| 10/30/2023 | Buy Now | 62.35% | Goldman Sachs | Chris Shibutani | $81 → $69 | Maintains | Buy | Get Alert |
| 10/27/2023 | Buy Now | 17.65% | Morgan Stanley | Terence Flynn | $56 → $50 | Maintains | Underweight | Get Alert |
| 10/27/2023 | Buy Now | 20% | Barclays | Carter Gould | $60 → $51 | Maintains | Equal-Weight | Get Alert |
| 10/27/2023 | Buy Now | 41.18% | BMO Capital | Evan Seigerman | → $60 | Downgrade | Outperform → Market Perform | Get Alert |
| 10/27/2023 | Buy Now | — | William Blair | Matt Phipps | — | Downgrade | Outperform → Market Perform | Get Alert |
| 10/27/2023 | Buy Now | 24.71% | HSBC | Rajesh Kumar | $55 → $53 | Upgrade | Reduce → Hold | Get Alert |
| 10/20/2023 | Buy Now | 41.18% | UBS | Trung Huynh | $70 → $60 | Assumes | Neutral → Neutral | Get Alert |
| 10/11/2023 | Buy Now | 31.76% | Morgan Stanley | Terence Flynn | $57 → $56 | Maintains | Underweight | Get Alert |
| 10/09/2023 | Buy Now | 76.47% | Cantor Fitzgerald | Olivia Brayer | → $75 | Reiterates | Overweight → Overweight | Get Alert |
| 10/06/2023 | Buy Now | 97.65% | Truist Securities | Robyn Karnauskas | → $84 | Reiterates | Buy → Buy | Get Alert |
| 09/15/2023 | Buy Now | 97.65% | Truist Securities | Gregg Gilbert | → $84 | Reiterates | Buy → Buy | Get Alert |
| 09/15/2023 | Buy Now | 55.29% | TD Cowen | Steve Scala | $80 → $66 | Maintains | Market Perform | Get Alert |
| 09/15/2023 | Buy Now | 76.47% | Cantor Fitzgerald | Olivia Brayer | → $75 | Reiterates | Overweight → Overweight | Get Alert |
| 07/28/2023 | Buy Now | 52.94% | Wells Fargo | Mohit Bansal | $78 → $65 | Maintains | Equal-Weight | Get Alert |
| 07/28/2023 | Buy Now | 85.88% | BMO Capital | Evan Seigerman | $87 → $79 | Maintains | Outperform | Get Alert |
| 07/28/2023 | Buy Now | 88.24% | B of A Securities | Geoff Meacham | $85 → $80 | Maintains | Buy | Get Alert |
| 07/28/2023 | Buy Now | 100% | Atlantic Equities | Steve Chesney | $90 → $85 | Maintains | Overweight | Get Alert |
| 07/28/2023 | Buy Now | 45.88% | Barclays | Carter Gould | $64 → $62 | Maintains | Equal-Weight | Get Alert |
| 07/20/2023 | Buy Now | 100% | Cantor Fitzgerald | Olivia Brayer | $88 → $85 | Maintains | Overweight | Get Alert |
| 07/19/2023 | Buy Now | 38.82% | Morgan Stanley | Terence Flynn | $59 → $59 | Reiterates | Underweight → Underweight | Get Alert |
| 07/14/2023 | Buy Now | 31.76% | HSBC | Rajesh Kumar | → $56 | Initiates | → Reduce | Get Alert |
| 07/11/2023 | Buy Now | 38.82% | Morgan Stanley | Terence Flynn | $59 → $59 | Reiterates | Underweight → Underweight | Get Alert |
| 07/11/2023 | Buy Now | 50.59% | Barclays | Carter Gould | $65 → $64 | Maintains | Equal-Weight | Get Alert |
| 07/10/2023 | Buy Now | 55.29% | SVB Leerink | David Risinger | → $66 | Initiates | → Market Perform | Get Alert |
| 06/28/2023 | Buy Now | 97.65% | Truist Securities | Gregg Gilbert | → $84 | Reiterates | Buy → Buy | Get Alert |
| 05/01/2023 | Buy Now | 52.94% | Barclays | Carter Gould | $66 → $65 | Maintains | Equal-Weight | Get Alert |
| 04/28/2023 | Buy Now | 69.41% | Credit Suisse | Trung Huynh | $78 → $72 | Maintains | Neutral | Get Alert |
| 04/21/2023 | Buy Now | 100% | B of A Securities | Geoff Meacham | $82 → $85 | Maintains | Buy | Get Alert |
| 03/06/2023 | Buy Now | 45.88% | Jefferies | Akash Tewari | → $62 | Initiates | → Hold | Get Alert |
| 02/03/2023 | Buy Now | 45.88% | Morgan Stanley | Terence Flynn | $60 → $62 | Maintains | Underweight | Get Alert |
| 02/03/2023 | Buy Now | 111.76% | Atlantic Equities | Steve Chesney | $88 → $90 | Maintains | Overweight | Get Alert |
| 01/17/2023 | Buy Now | 123.53% | Cantor Fitzgerald | Olivia Brayer | → $95 | Initiates | → Overweight | Get Alert |
| 01/03/2023 | Buy Now | 83.53% | Wells Fargo | Mohit Bansal | $70 → $78 | Maintains | Equal-Weight | Get Alert |
| 11/18/2022 | Buy Now | 83.53% | Credit Suisse | Trung Huynh | → $78 | Initiates | → Neutral | Get Alert |
| 11/10/2022 | Buy Now | 107.06% | Atlantic Equities | Steve Chesney | $85 → $88 | Maintains | Overweight | Get Alert |
| 10/27/2022 | Buy Now | 41.18% | Morgan Stanley | Terence Flynn | $61 → $60 | Maintains | Underweight | Get Alert |
| 10/27/2022 | Buy Now | 100% | Atlantic Equities | Steve Chesney | $87 → $85 | Maintains | Overweight | Get Alert |
| 10/12/2022 | Buy Now | 55.29% | Barclays | Carter Gould | $69 → $66 | Maintains | Equal-Weight | Get Alert |
| 10/10/2022 | Buy Now | — | Guggenheim | Seamus Fernandez | — | Downgrade | Buy → Neutral | Get Alert |
| 09/14/2022 | Buy Now | 78.82% | Berenberg | Luisa Hector | $82 → $76 | Downgrade | Buy → Hold | Get Alert |
| 09/12/2022 | Buy Now | 121.18% | BMO Capital | Evan Seigerman | $92 → $94 | Maintains | Outperform | Get Alert |
| 09/12/2022 | Buy Now | 104.71% | Atlantic Equities | Steve Chesney | $83 → $87 | Maintains | Overweight | Get Alert |
| 07/28/2022 | Buy Now | 43.53% | Morgan Stanley | Terence Flynn | $63 → $61 | Maintains | Underweight | Get Alert |
| 07/28/2022 | Buy Now | 76.47% | UBS | Colin Bristow | $73 → $75 | Maintains | Neutral | Get Alert |
| 07/28/2022 | Buy Now | 95.29% | Atlantic Equities | Steve Chesney | $82 → $83 | Maintains | Overweight | Get Alert |
| 06/06/2022 | Buy Now | — | Raymond James | Dane Leone | — | Downgrade | Outperform → Market Perform | Get Alert |
| 06/03/2022 | Buy Now | — | Raymond James | Dane Leone | — | Downgrade | Outperform → Market Perform | Get Alert |
| 05/26/2022 | Buy Now | 111.76% | Citigroup | Andrew Baum | $75 → $90 | Maintains | Buy | Get Alert |
| 05/17/2022 | Buy Now | 64.71% | Wells Fargo | Mohit Bansal | $65 → $70 | Maintains | Equal-Weight | Get Alert |
| 05/02/2022 | Buy Now | 116.47% | BMO Capital | Evan Seigerman | $87 → $92 | Maintains | Outperform | Get Alert |
| 05/02/2022 | Buy Now | 48.24% | Morgan Stanley | Terence Flynn | $64 → $63 | Maintains | Underweight | Get Alert |
| 05/02/2022 | Buy Now | 60% | Barclays | Carter Gould | $66 → $68 | Maintains | Equal-Weight | Get Alert |
| 04/06/2022 | Buy Now | 50.59% | Morgan Stanley | Terence Flynn | $66 → $64 | Downgrade | Equal-Weight → Underweight | Get Alert |
| 03/30/2022 | Buy Now | 90.59% | BMO Capital | Evan Seigerman | $74 → $81 | Maintains | Outperform | Get Alert |
| 03/02/2022 | Buy Now | 52.94% | Wells Fargo | Mohit Bansal | $60 → $65 | Maintains | Equal-Weight | Get Alert |
| 12/17/2021 | Buy Now | 69.41% | Goldman Sachs | Chris Shibutani | — | Initiates | → Buy | Get Alert |
| 12/09/2021 | Buy Now | 36.47% | Wells Fargo | Mohit Bansal | — | Initiates | → Equal-Weight | Get Alert |
| 11/19/2021 | Buy Now | 69.41% | BMO Capital | Evan Seigerman | — | Initiates | → Outperform | Get Alert |
| 11/01/2021 | Buy Now | — | Argus Research | David Toung | — | Downgrade | Buy → Hold | Get Alert |
| 10/28/2021 | Buy Now | 55.29% | Barclays | Carter Gould | — | Maintains | Equal-Weight | Get Alert |
| 10/12/2021 | Buy Now | 55.29% | Morgan Stanley | Matthew Harrison | — | Maintains | Equal-Weight | Get Alert |
| 10/11/2021 | Buy Now | 67.06% | Berenberg | — | — | Maintains | Buy | Get Alert |
| 10/08/2021 | Buy Now | 60% | Barclays | Carter Gould | — | Maintains | Equal-Weight | Get Alert |
| 07/29/2021 | Buy Now | 67.06% | Morgan Stanley | Matthew Harrison | — | Maintains | Equal-Weight | Get Alert |
FAQ
What is the target price for Bristol-Myers Squibb (BMY) stock?
The latest price target for Bristol-Myers Squibb (NYSE:BMY) was reported by Barclays on July 10, 2024. The analyst firm set a price target for $41.00 expecting BMY to fall to within 12 months (a possible -3.53% downside). 29 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Bristol-Myers Squibb (BMY)?
The latest analyst rating for Bristol-Myers Squibb (NYSE:BMY) was provided by Barclays, and Bristol-Myers Squibb maintained their equal-weight rating.
When was the last upgrade for Bristol-Myers Squibb (BMY)?
The last upgrade for Bristol-Myers Squibb Co happened on October 27, 2023 when HSBC raised their price target to $53. HSBC previously had a reduce for Bristol-Myers Squibb Co.
When was the last downgrade for Bristol-Myers Squibb (BMY)?
The last downgrade for Bristol-Myers Squibb Co happened on February 6, 2024 when Redburn Atlantic changed their price target from $77 to $54 for Bristol-Myers Squibb Co.
When is the next analyst rating going to be posted or updated for Bristol-Myers Squibb (BMY)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bristol-Myers Squibb, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bristol-Myers Squibb was filed on July 10, 2024 so you should expect the next rating to be made available sometime around July 10, 2025.
Is the Analyst Rating Bristol-Myers Squibb (BMY) correct?
While ratings are subjective and will change, the latest Bristol-Myers Squibb (BMY) rating was a maintained with a price target of $43.00 to $41.00. The current price Bristol-Myers Squibb (BMY) is trading at is $42.50, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.